| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bicalutamide | GDSC1000 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | 0.024 | 0.6 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | 0.028 | 0.6 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | -0.019 | 0.6 |